beetle Le aoe ue Relat ouoelscee

Etiologies of FSGS

ed Due at mn fur)

Iciopathic FSCS, Histology: ~ 80% NOS, ~ 10% CG, ~ 5% Circulating Factor, various candidates, none confirmed; 28242845
TIP,~ SPH, 1%CV;FPE>40% | recursin transplants 25447132

CCongenitalnephroticsyncrome May have only DMS 73 oF familial SRNS; milder cases reportedin adulthood 19812541
(Finnish) NPHS? (aR) 26195142

Podocin deficiency NAWS2 May have diffuse mesangial 10% offamilal SANS; chichood or congenital 7% oF | 24856360

        

byperceliularty without FSGS sporadic FSGS in children; + NPHS1 mutations (AR) 29474669
Phospholipase Cet LCE? DMS 18-40% 2% of familial SRNS (AR); not Found in sporadic FSCS 25349199
Familial collapsing FSGS TRPCS CG (0.5% of ferilial RNS (AR); ESRD >21 years (AD) 23689571
CCD2AP deficiency co24P CG; diffuse mesangial gM Heterozygote in~ 3% sporadic SRNS (AR) 1713465,
actin d ACTING Podooyte ejtoplasmic aggregates Adult onset, may have hematuria (AD) ast
‘Apolipoprotein Lt APOL1 2G1 and G2 riskallelesin 10-15% of African Americans, 29389775

affects other renal diseases, donor kidneys (AR)

Dent disease CLONS CaPhos; metachromatic casts Hypercalciria, tubular proteinuria (x) 24810952
‘Other genes (rare) Scant pathology information ‘ANLN, ARHGAP24, ARHGDIA, EMP2, LAMAS, MAGI2, MYOTE, 29127259

ODM, PTPRO, T7218,

   
         

 

   

Autosomal dominant FSCS IN2 NOS, CC,minimal change disease; | 05% of arial SNS; 12% have Charcot MaieTooth (AD 20023659
jagged foot processes does nt recurin transplants 20038087 ||
Frasier and Denys-Drash ‘PH, NOS; DMS common (23%) 4.8% of familial SRNS; Wms tumor (Denys-Drash);male | 27596598)
syndromes WIT (especially Denys-Drash) Pseudohermaphroditism (Frasier); (AD) |
Pierson syndrome LAMB2 DMS 14% 1% of Familial SRNS; microcoria (AR) 29673759
Alport syndrome COL4A3, NOS or PH; GBM irregularities not Familial FSGS with proteinuria, hematuria (AR, X); may beno 25229338
COLMAS diagnostic of Alport ‘eye or hearing signs; estimated ~ 10% of familial FSGS. 21908087
Schimke immunoosseous | CG, TP; TUNEL + podocytes parietal | Tell defienc,spondYoepiphyseal dysplasia, 09% oF 25319549
dysplasia SMARCAL 1 and tubular epithelium familial SRNS (AR)
Naitpatela syndrome UMx16 Banded collagenin GBM #5GS can occur without exrarenalsigns (AD) 23687361
Galloway Mowat WOR73/ CG, DMS Microcephaly (AR) 25873735
Epidermolysis bullosa /TGA3/B4 Childhood onset (AR) 24902943
Epstein echtner Mr Deafness, leukocyte inclusions, macroplatelets (AR) 2r210183
Fabry dsease CLA CG,NOS; EM lipid inclusions Late change 00 29960669
CoQt0 deficiency COg2, :dysmorphic mitochondria (0.2% oF Familial SRNS (AR) hearing los; treated with oral 17855635
C0088, Cogs, POSS2, ADK cogto 2searer
MELAS syndrome (MI-TL1,2.9) NOS; dysmorphic mitochondria Encephalomyopathy, lactic acidosis stroke-ike episodes | 29190634)
Nuclear pore NUP93, NUP2OS, Microcephaly (AR) 27190346
‘MUPIO7, XPOS
Other genes (rare) Scant pathology information ALG1, C151, CRB2, CUBN, EVA}, KBKAP, KANK.2 27987848
LUNA, NES, PaN2, PM, SCARB2 SPCLT, ZMPSTE24
Hiv CG,TRS, tubular dation infitrate Associated with APOL iskalleles 29236630
Parvovirus B19 CG, TRS, tubular dilation, infiltrate Associated with APOL 1 riskalleles. 27600725)
omy C6, TP, abundant TRS ‘Associated with APOL sales 26849629
HOV NOS, CG Direct acting antiviral treatment 28211090")
Tuberculosis CG,NOS 23594601 |
Filariasis (Log log) CG; microfilariae in vessels 22325313
‘Schistosomiasis cG Black race risk Factor, persists after schistosomal therapy 22124564.
a 2 Te z =
Interferon (a By) Abundant endothelial TRS 100% APOLrskalees;improved after drug withdrawal 20203168

Lithium Microgsts Progression even with drug withdrawalifCr> 2.5 10906157)